DALLAS, July 30, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring healthcare/drug company Cannabis Science Inc. (OTCBB:CBIS). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Cannabis Science Inc. (OTCBB:CBIS) should be of particular interest to other healthcare/drug companies: Mylan Inc. (NYSE:MYL), Watson Pharmaceuticals Inc. (NYSE:WPI), Par Pharmaceutical Companies Inc. (NYSE:PRX) and Caraco Pharmaceutical Laboratories Ltd. (NYSE:CPD).
It is available at: http://www.beaconequity.com/i/CBIS
Get our alerts BEFORE the rest of the market.Follow us on Twitter: http://twitter.com/BeaconEquity
Cannabis Science Inc. (CBIS) is an emerging pharmaceutical company focused on the development and commercialization of phytocannabinoid for the treatment of various neuro-muscular disorders; neuropathic pain related to spinal cord injuries; pain related to AIDS/HIV; respiratory pain related to AIDS/HIV, influenza and autoimmune diseases of asthma and cancer; digestive disorders such as Crohn's disease, irritable bowel syndrome and dermatological infections; as well as sleep disorders.
In the report, the analyst notes:
"Regarding the pain relief market, the Company's strength comes from the weakness in the top three over-the-counter drugs acetaminophen (Tylenol) made by Johnson & Johnson, Bayer's acetylsalicylic acid (Asprin) and ibuprofen (Advil) made by Wyeth. In the case of Tylenol, sudden liver failure has happened in many patients affected by the drug.
"Total sales of all pain relief drugs in the United States is expected to reach $40 billion next year, with more than 80% of the market coming from over-the-counter products, according to a March 2003 Nature Reviews Drug Discovery magazine. CBIS has received a lot of attention from investors due to the response to the rapid spread of the H1N1 virus reported by the WHO, which recent elevated its warning to world pandemic level six."
To read the entire report visit: http://www.beaconequity.com/i/CBIS
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.